Oncomine Breast cfTNA Assay: Advanced Liquid Biopsy for Breast Cancer
Introduction to Oncomine Breast cfTNA Assay
The Oncomine Breast cfTNA Assay represents a groundbreaking advancement in breast cancer diagnostics, offering a non-invasive approach to comprehensive genomic profiling. This innovative liquid biopsy test analyzes circulating tumor nucleic acids (cfTNA) from a simple blood sample, providing critical insights into breast cancer biology without the need for invasive tissue biopsies. As breast cancer treatment becomes increasingly personalized, this assay delivers essential molecular information to guide targeted therapy decisions and monitor treatment response throughout the cancer journey.
What Does the Test Measure and Detect?
The Oncomine Breast cfTNA Assay utilizes next-generation sequencing (NGS) technology to comprehensively analyze circulating tumor DNA and RNA from peripheral blood. This sophisticated test detects:
- Key mutations in breast cancer driver genes including ESR1, PIK3CA, and TP53
- Gene amplifications such as HER2 and FGFR1
- Gene fusions involving critical breast cancer pathways
- Single nucleotide variants and insertions/deletions across multiple cancer-related genes
- Copy number variations relevant to breast cancer progression
Who Should Consider This Test?
The Oncomine Breast cfTNA Assay is particularly valuable for individuals with:
- Metastatic breast cancer requiring treatment selection guidance
- History of breast cancer undergoing routine monitoring
- Suspected treatment resistance or disease progression
- Limited tissue availability for comprehensive genomic testing
- Need for serial monitoring of treatment response
- Concerns about invasive biopsy procedures
Benefits of Taking the Oncomine Breast cfTNA Assay
This advanced liquid biopsy offers numerous advantages for breast cancer management:
- Non-Invasive Procedure: Simple blood draw eliminates risks associated with tissue biopsies
- Comprehensive Genomic Profiling: Simultaneous analysis of multiple genomic alterations
- Real-Time Monitoring: Enables serial testing to track treatment response and resistance
- Early Detection of Resistance: Identifies emerging resistance mechanisms before clinical progression
- Minimal Residual Disease Detection: Sensitive detection of low-level disease after treatment
- Guided Therapy Selection: Provides molecular information for targeted treatment decisions
Understanding Your Test Results
Your Oncomine Breast cfTNA Assay results will provide detailed information about detected genomic alterations. Positive results indicate the presence of specific mutations, amplifications, or fusions that may guide treatment decisions. Negative results suggest no detectable circulating tumor nucleic acids at the time of testing, though this does not rule out the presence of disease. All results should be discussed with your healthcare provider in the context of your complete clinical picture. Our genetic counselors are available to help interpret complex findings and discuss implications for your treatment plan.
Test Pricing and Details
| Test Component | Details |
|---|---|
| Test Name | Oncomine Breast cfTNA Assay |
| Regular Price | $1750 USD |
| Discount Price | $1312 USD |
| Turnaround Time | 2-3 weeks |
| Sample Type | Peripheral blood (10 ml) |
| Technology | Next-Generation Sequencing (NGS) |
Nationwide Availability
We have branches across all major cities in the United States, including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art facilities ensure consistent, high-quality testing services with convenient locations for patients nationwide.
Book Your Test Today
Take the next step in your breast cancer journey with the advanced Oncomine Breast cfTNA Assay. Our experienced team is ready to assist you with scheduling and answer any questions about this revolutionary liquid biopsy test. Contact us today to schedule your appointment and benefit from comprehensive genomic insights for personalized breast cancer management.
Call or WhatsApp: +1(267) 388-9828
Important Note: The Oncomine Breast cfTNA Assay requires a doctor’s prescription. Prescription requirements do not apply for surgery and pregnancy cases or individuals planning to travel abroad. Please consult with your healthcare provider to determine if this test is appropriate for your specific situation.
